Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Koate DVI
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : WuXi Biologics
Deal Size : Undisclosed
Deal Type : Acquisition
WuXi Biologics and Bayer enter into acquisition agreement
Details : First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities. WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 16, 2020
Lead Product(s) : Koate DVI
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : WuXi Biologics
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?